Tango Therapeutics
Highly Engaged Employees
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
201 Brookline Ave Ste 901, Boston, Massa...Phone Number
(857) 320-4900Website
www.tangotx.comRevenue
$57 MillionStock Symbol
TNGXIndustry
About Tango Therapeutics
Tango Therapeutics Org Chart
Is Tango Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Tango Therapeutics had a recent Job posting/layoffs
Tango Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Tango Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Tango Therapeutics is spiking on competitors!
Earning: See what the market has to say on Tango Therapeutics recently announced quarterly report
Product Launch: Get notified when Tango Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Tango Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Tango Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Tango Therapeutics
Compare insights from companies similar to Tango Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Tango Therapeutics
Company Profile Activity
Activity Insights
Tango Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Tango Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Tango Therapeutics.
Tango Therapeutics financials insights
Gather financial insights about Tango Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Private Equity
$50M
Other Financing Round
$165M
Stock/Share Issuance
$225M
Stock/Share Issuance
$15M
Tango Therapeutics Tech Stack
A closer look at the technologies used by Tango Therapeutics
Most Recent Scoops
Tango Therapeutics News & Media
Tango Therapeutics Announces Executive Chair Transition
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Dr. Barbara Weber, the Executive Chairman of the Board of Directors of Tango Therapeutics, will be stepping down in connection with other pursuits.Tango Therapeutics Appoints Robert Azelby to Board of Directors
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings more than three decades of leadership experience across the biopharmaceutical industry, including deep expertise in oncology commercialization, corporate strategy, company building and board goTango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stock (the “Offering”). The offering price of each share of common stock is $30.00. The offering price of eTango Therapeutics Announces Proposed $500 Million Public Offering
BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the launch of an underwritten public offering (the “Offering”) of $500 million of its common stock. All shares of common stock to be sold in the Offering will be offered by Tango. Tango also intends to grant the underwriters a 30-day option to purchase
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision oncology therapies. The company leverages genetic insights and targeted drug discovery to develop novel cancer treatments for genetically defined patient populations with significant unmet medical needs.... Read More


